Cargando…

Treatment satisfaction and quality of life in patients treated with fingolimod

BACKGROUND: The development of oral treatments for relapsing–remitting multiple sclerosis (RRMS) may alter patient satisfaction and quality of life (QoL). The aim of this survey was to evaluate treatment satisfaction and QoL in patients treated with fingolimod in everyday clinical practice in France...

Descripción completa

Detalles Bibliográficos
Autores principales: Mékiès, Claude, Heinzlef, Olivier, Jenny, Béatrice, Ramelli, Anne-Laure, Clavelou, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973401/
https://www.ncbi.nlm.nih.gov/pubmed/29872275
http://dx.doi.org/10.2147/PPA.S144021
_version_ 1783326622382817280
author Mékiès, Claude
Heinzlef, Olivier
Jenny, Béatrice
Ramelli, Anne-Laure
Clavelou, Pierre
author_facet Mékiès, Claude
Heinzlef, Olivier
Jenny, Béatrice
Ramelli, Anne-Laure
Clavelou, Pierre
author_sort Mékiès, Claude
collection PubMed
description BACKGROUND: The development of oral treatments for relapsing–remitting multiple sclerosis (RRMS) may alter patient satisfaction and quality of life (QoL). The aim of this survey was to evaluate treatment satisfaction and QoL in patients treated with fingolimod in everyday clinical practice in France. METHODS: Neurologists treating MS in France were invited to participate in the survey by telephone. Each physician was expected to recruit up to six patients with RRMS currently being treated with fingolimod. Enrolled patients were asked to complete the Treatment Satisfaction Questionnaire for Medication (TSQM), the 3-level 5-dimension EuroQoL instrument, as well as specific questions on change in QoL since starting fingolimod. Factors associated with the TSQM score were evaluated using multiple logistic regression analysis. RESULTS: Two hundred and fourteen patients were recruited by 54 neurologists. The mean age of the patients was 41.6±10.0 years, and 73.4% of them were women. During the hospitalization for initiation of fingolimod treatment, 70.1% of patients had received information on MS, 76.6% had received information on fingolimod, and 20.7% had participated in a therapeutic education program. The two variables with the strongest associations with high TSQM scores (≥75) were a positive perception of initial hospitalization (hazard ratio: 10.27) and receiving information on MS during hospitalization (hazard ratio: 5.70). The mean EQ-visual analog scale score was 71.6±16.8. The mean EQ-visual analog scale score was significantly higher in patients satisfied with their treatment (75.8±15.2) compared to those unsatisfied with treatment (66.6±17.2). The proportion of patients who reported an improvement in their capacity to plan for the future was higher in satisfied (72.6%) than in unsatisfied patients (49.5%). CONCLUSION: The majority of patients treated with fingolimod are satisfied with their treatment. Treatment satisfaction is associated with better self-rated QoL and an improvement of QoL since starting treatment.
format Online
Article
Text
id pubmed-5973401
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59734012018-06-05 Treatment satisfaction and quality of life in patients treated with fingolimod Mékiès, Claude Heinzlef, Olivier Jenny, Béatrice Ramelli, Anne-Laure Clavelou, Pierre Patient Prefer Adherence Original Research BACKGROUND: The development of oral treatments for relapsing–remitting multiple sclerosis (RRMS) may alter patient satisfaction and quality of life (QoL). The aim of this survey was to evaluate treatment satisfaction and QoL in patients treated with fingolimod in everyday clinical practice in France. METHODS: Neurologists treating MS in France were invited to participate in the survey by telephone. Each physician was expected to recruit up to six patients with RRMS currently being treated with fingolimod. Enrolled patients were asked to complete the Treatment Satisfaction Questionnaire for Medication (TSQM), the 3-level 5-dimension EuroQoL instrument, as well as specific questions on change in QoL since starting fingolimod. Factors associated with the TSQM score were evaluated using multiple logistic regression analysis. RESULTS: Two hundred and fourteen patients were recruited by 54 neurologists. The mean age of the patients was 41.6±10.0 years, and 73.4% of them were women. During the hospitalization for initiation of fingolimod treatment, 70.1% of patients had received information on MS, 76.6% had received information on fingolimod, and 20.7% had participated in a therapeutic education program. The two variables with the strongest associations with high TSQM scores (≥75) were a positive perception of initial hospitalization (hazard ratio: 10.27) and receiving information on MS during hospitalization (hazard ratio: 5.70). The mean EQ-visual analog scale score was 71.6±16.8. The mean EQ-visual analog scale score was significantly higher in patients satisfied with their treatment (75.8±15.2) compared to those unsatisfied with treatment (66.6±17.2). The proportion of patients who reported an improvement in their capacity to plan for the future was higher in satisfied (72.6%) than in unsatisfied patients (49.5%). CONCLUSION: The majority of patients treated with fingolimod are satisfied with their treatment. Treatment satisfaction is associated with better self-rated QoL and an improvement of QoL since starting treatment. Dove Medical Press 2018-05-22 /pmc/articles/PMC5973401/ /pubmed/29872275 http://dx.doi.org/10.2147/PPA.S144021 Text en © 2018 Mékiès et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Mékiès, Claude
Heinzlef, Olivier
Jenny, Béatrice
Ramelli, Anne-Laure
Clavelou, Pierre
Treatment satisfaction and quality of life in patients treated with fingolimod
title Treatment satisfaction and quality of life in patients treated with fingolimod
title_full Treatment satisfaction and quality of life in patients treated with fingolimod
title_fullStr Treatment satisfaction and quality of life in patients treated with fingolimod
title_full_unstemmed Treatment satisfaction and quality of life in patients treated with fingolimod
title_short Treatment satisfaction and quality of life in patients treated with fingolimod
title_sort treatment satisfaction and quality of life in patients treated with fingolimod
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973401/
https://www.ncbi.nlm.nih.gov/pubmed/29872275
http://dx.doi.org/10.2147/PPA.S144021
work_keys_str_mv AT mekiesclaude treatmentsatisfactionandqualityoflifeinpatientstreatedwithfingolimod
AT heinzlefolivier treatmentsatisfactionandqualityoflifeinpatientstreatedwithfingolimod
AT jennybeatrice treatmentsatisfactionandqualityoflifeinpatientstreatedwithfingolimod
AT ramelliannelaure treatmentsatisfactionandqualityoflifeinpatientstreatedwithfingolimod
AT claveloupierre treatmentsatisfactionandqualityoflifeinpatientstreatedwithfingolimod